Trial · NCT00433511
Adverse events1,400
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,400
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm A (Chemo + Placebo) | 37 | 972 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm B (Chemo + Bevacizumab) | 103 | 1,922 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 87 | 1,942 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm D (Bevacizumab Cycles 9-18 of Arm C) | 64 | 1,168 | |
| other | Neuropathy-sensory | Nervous system disorders | Arm A (Chemo + Placebo) | 188 | 972 | |
| other | Neuropathy-sensory | Nervous system disorders | Arm B (Chemo + Bevacizumab) | 356 | 1,922 | |
| other | Neuropathy-sensory | Nervous system disorders | Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 334 | 1,942 | |
| other | Neuropathy-sensory | Nervous system disorders | Arm D (Bevacizumab Cycles 9-18 of Arm C) | 182 | 1,168 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm A (Chemo + Placebo) | 52 | 972 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm B (Chemo + Bevacizumab) | 117 | 1,922 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 119 | 1,942 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm D (Bevacizumab Cycles 9-18 of Arm C) | 0 | 1,168 | |
| serious | Allergic reaction | Immune system disorders | Arm A (Chemo + Placebo) | 12 | 972 | |
| serious | Allergic reaction | Immune system disorders | Arm B (Chemo + Bevacizumab) | 16 | 1,922 | |
| serious | Allergic reaction | Immune system disorders | Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 16 | 1,942 | |
| serious | Allergic reaction | Immune system disorders | Arm D (Bevacizumab Cycles 9-18 of Arm C) | 1 | 1,168 | |
| serious | Hearing w/o audiogr not in monitor prg | Ear and labyrinth disorders | Arm A (Chemo + Placebo) | 0 | 972 | |
| serious | Hearing w/o audiogr not in monitor prg | Ear and labyrinth disorders | Arm B (Chemo + Bevacizumab) | 0 | 1,922 | |
| serious | Hearing w/o audiogr not in monitor prg | Ear and labyrinth disorders | Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 1 | 1,942 | |
| serious | Hearing w/o audiogr not in monitor prg | Ear and labyrinth disorders | Arm D (Bevacizumab Cycles 9-18 of Arm C) | 0 | 1,168 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00433511/events